Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289852 | 0.83 | SCN9A (1.00) | SCN9AKDM4EALDH1A1GAA | |
| SCHEMBL1289764 | 0.83 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1289745 | 0.83 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1289813 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1289810 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL27906842 | 0.81 | SCN9A (0.79) | SCN9AKDM4EALDH1A1GAA | |
| SCHEMBL1289734 | 0.80 | SCN9A (1.00) | SCN9AKDM4EALDH1A1GAA | |
| SCHEMBL1289766 | 0.80 | SCN9A (1.00) | SCN9AKDM4EALDH1A1GAA | |
| SCHEMBL1289735 | 0.80 | SCN9A (1.00) | SCN9AKDM4EALDH1A1GAA | |
| SCHEMBL1289695 | 0.79 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | claimed |
| US-9045435-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-06-02 | — | — | US | claimed |
| EP-2625169-B1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2015-03-25 | — | — | EP | claimed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | claimed |
| EP-2625169-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2013-08-14 | — | — | EP | claimed |
| CN-103168033-A | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA LP | 2013-06-19 | — | — | CN | claimed |
| WO-2012046132-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-04-12 | — | — | WO | claimed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2625169-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2013-08-14 | — | — | EP | disclosed |
| CN-103168033-A | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA LP | 2013-06-19 | — | — | CN | disclosed |
| WO-2012046132-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012046132-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | SCN4A, TRPV1, SCN1B | SCN9A 59/4885KDM4E 1470/4885ALDH1A1 774/4885 |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN4A, TRPV1, SCN1B | SCN9A 59/4885KDM4E 1470/4885ALDH1A1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.